Current Hematologic Malignancy Reports

, Volume 7, Issue 1, pp 57–64 | Cite as

Role of TET2 Mutations in Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (JJ Kiladjian, Section Editor)

Abstract

Recently, 5-hydroxymethylcytosine (5-hmC), the 6th base of DNA, was discovered as the product of the hydroxylation of 5-methylcytosine (5-mC) by the ten-eleven translocation (TET) oncogene family members. One of them, TET oncogene family member 2 (TET2), is mutated in a variety of myeloid malignancies, including in 15% of myeloproliferative neoplasms (MPNs). Recent studies tried to go further into the biological and epigenetic function of TET2 protein and 5-hmC marks in the pathogenesis of myeloid malignancies. Although its precise function remains partially unknown, TET2 appears to be an important regulator of hematopoietic stem cell biology. In both mouse and human cells, its inactivation leads to a dramatic deregulation of hematopoiesis that ultimately triggers blood malignancies. Understanding this leukemogenic process will provide tools to develop new epigenetic therapies against blood cancers.

Keywords

TET2 Mutations 5-hydroxymethylcytosine Myeloproliferative neoplasms Myeloid malignancies Hematopoietic stem cells Epigenetics Pathogenesis 

Notes

Acknowledgements

The authors are grateful to the MPN research foundation, the Fondation de France, the Institut National du Cancer, the Ligue Nationale Contre le Cancer, the Association pour la Recherche sur le Cancer, and the French Ministry of Research.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Bird A. The essentials of DNA methylation. Cell. 1992;70:5–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet. 1997;13:444–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Siegfried Z, Cedar H. DNA methylation: A molecular lock. Curr Biol. 1997;7:R305–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–30.PubMedCrossRefGoogle Scholar
  7. 7.
    •• Tahiliani M, Koh KP, Shen Y, et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930–935. Discovery of TET1 catalytic activity by homology with the trypanosome enzymes JBP1 and JBP2. Tahiliani et al. demonstrate for the first time the ability of a mammalian dioxygenase to convert 5-mC into 5-hmC. PubMedCrossRefGoogle Scholar
  8. 8.
    Lorsbach RB, Moore J, Mathew S, et al. Tet1, a member of a novel protein family, is fused to mll in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17:637–41.PubMedCrossRefGoogle Scholar
  9. 9.
    • Ito S, D’Alessio AC, Taranova OV, et al.: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129–1133. Ito et al. show that Tet1, Tet2, and Tet3 share the same catalytic activity and play a role in the transcription control of development genes. PubMedCrossRefGoogle Scholar
  10. 10.
    •• Delhommeau F, Dupont S, Della Valle V, et al.: Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289–2301. First evidence for mutations in TET2 in myeloid malignancies, including MPN. Shows a selective advantage of TET2 mutant cells over TET2 wild-type cells in severe combined immunodeficiency repopulation assays. PubMedCrossRefGoogle Scholar
  11. 11.
    •• Langemeijer SM, Kuiper RP, Berends M, et al.: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838–842. Large study of TET2 mutations in MDS and TET2 expression studies. Evidence for the modulation of TET2 during granulocytic differentiation. PubMedCrossRefGoogle Scholar
  12. 12.
    Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23:1343–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Tefferi A, Pardanani A, Lim KH, et al. Tet2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905–11.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Ko M, Huang Y, Jankowska AM, et al.: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant tet2. Nature 2010;468:839–843. Evidence that patients with TET2 mutations have low 5-hmC levels and an abnormal DNA methylation profile. PubMedCrossRefGoogle Scholar
  16. 16.
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Vardiman JW. Chronic myelogenous leukemia, bcr-abl1+. Am J Clin Pathol. 2009;132:250–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Tefferi A, Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2010;29:573–82.CrossRefGoogle Scholar
  19. 19.
    Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase jak2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMedGoogle Scholar
  20. 20.
    James C, Ugo V, Le Couedic JP, et al. A unique clonal jak2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of jak2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.PubMedCrossRefGoogle Scholar
  23. 23.
    Scott LM, Tong W, Levine RL, et al. Jak2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.PubMedCrossRefGoogle Scholar
  24. 24.
    Pardanani AD, Levine RL, Lasho T, et al. Mpl515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Pikman Y, Lee BH, Mercher T, et al. Mplw515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.PubMedCrossRefGoogle Scholar
  26. 26.
    Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor ikaros in myeloproliferative neoplasms. Leukemia. 2010;24:1290–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein lnk drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114:144–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Viguie F, Aboura A, Bouscary D, et al. Common 4q24 deletion in four cases of hematopoietic malignancy: Early stem cell involvement? Leukemia. 2005;19:1411–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117:e198–206.PubMedCrossRefGoogle Scholar
  35. 35.
    Roche-Lestienne C, Marceau A, Labis E, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2010;96:367–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114:1628–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115:2003–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Koh KP, Yabuuchi A, Rao S, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011;8:200–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Clouaire T, de Las Heras JI, Merusi C, Stancheva I. Recruitment of MBD1 to target genes requires sequence-specific interaction of the MBD domain with methylated DNA. Nucleic Acids Res. 2010;38:4620–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Nakao M, Matsui S, Yamamoto S, et al. Regulation of transcription and chromatin by methyl-CPG binding protein MBD1. Brain Dev. 2001;23 Suppl 1:S174–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Young SR, Skalnik DG. CXXC finger protein 1 is required for normal proliferation and differentiation of the PLB-985 myeloid cell line. DNA Cell Biol. 2007;26:80–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated idh1 and idh2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–34.PubMedCrossRefGoogle Scholar
  45. 45.
    • Figueroa ME, Abdel-Wahab O, Lu C, et al.: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567. Evidence that IDH1/2 and TET2 mutations impair hematopoietic differentiation in a similar way. PubMedCrossRefGoogle Scholar
  46. 46.
    Ito S, Shen L, Dai Q, et al. TET proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–3.PubMedCrossRefGoogle Scholar
  47. 47.
    • Pronier E, Almire C, Mokrani H, et al.: Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011;118:2551–2555. Demonstration that MPN patients with TET2 mutations have low DNA contents of 5-hmC, and that TET2 depletion in human progenitors leads to abnormal myeloid differentiation. PubMedCrossRefGoogle Scholar
  48. 48.
    Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97.PubMedCrossRefGoogle Scholar
  49. 49.
    Penn NW, Suwalski R, O’Riley C, et al. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J. 1972;126:781–90.PubMedGoogle Scholar
  50. 50.
    Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids. 2011;2011:870726.PubMedGoogle Scholar
  51. 51.
    Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011;473:398–402.PubMedCrossRefGoogle Scholar
  52. 52.
    Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011;473:394–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Robertson J, Robertson AB, Klungland A. The presence of 5-hydroxymethylcytosine at the gene promoter and not in the gene body negatively regulates gene expression. Biochem Biophys Res Commun. 2011;411:40–3.PubMedCrossRefGoogle Scholar
  54. 54.
    Stroud H, Feng S, Morey Kinney S, et al. 5-hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol. 2011;12:R54.PubMedCrossRefGoogle Scholar
  55. 55.
    Szulwach KE, Li X, Li Y, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. 2011;7:e1002154.PubMedCrossRefGoogle Scholar
  56. 56.
    • Williams K, Christensen J, Pedersen MT, et al.: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473:343–348. Mapping of 5-hmC and TET1 localization: consequences for transcription and methylation. PubMedCrossRefGoogle Scholar
  57. 57.
    Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007;67:946–50.PubMedCrossRefGoogle Scholar
  58. 58.
    Jin SG, Kadam S, Pfeifer GP. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res. 2010;38:e125.PubMedCrossRefGoogle Scholar
  59. 59.
    Guo JU, Su Y, Zhong C, et al. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. 2011;145:423–34.PubMedCrossRefGoogle Scholar
  60. 60.
    Cortellino S, Xu J, Sannai M, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell. 2011;146:67–79.PubMedCrossRefGoogle Scholar
  61. 61.
    • Quivoron C, Couronne L, Della Valle V, et al.: Tet2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25–38. Description of two Tet2 gene-disrupted mouse models with dramatic consequences on HSCs and both myeloid and lymphoid differentiations. First description of TET2 mutations in human B and T lymphomas. PubMedCrossRefGoogle Scholar
  62. 62.
    Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509–18.PubMedCrossRefGoogle Scholar
  64. 64.
    Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (tet2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A. 2011;108:14566–71.PubMedCrossRefGoogle Scholar
  65. 65.
    Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803–10.PubMedCrossRefGoogle Scholar
  66. 66.
    Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25:877–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer And Leukemia Group B study. J Clin Oncol. 2011;29:1373–81.PubMedCrossRefGoogle Scholar
  68. 68.
    Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116:1132–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593–603.PubMedCrossRefGoogle Scholar
  70. 70.
    Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116:3923–32.PubMedCrossRefGoogle Scholar
  71. 71.
    Tefferi A. Mutational analysis in bcr-abl-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leuk Lymphoma. 2010;51:576–82.PubMedCrossRefGoogle Scholar
  72. 72.
    Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70:447–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a jak2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891–900.PubMedCrossRefGoogle Scholar
  74. 74.
    Nguyen-Khac F, Lesty C, Eclache V, et al. Chromosomal abnormalities in transformed ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer. 2010;49:919–27.PubMedCrossRefGoogle Scholar
  75. 75.
    Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35.PubMedCrossRefGoogle Scholar
  76. 76.
    Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519–23.PubMedCrossRefGoogle Scholar
  77. 77.
    Couronne L, Lippert E, Andrieux J, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010;24:201–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Université Pierre et Marie Curie (Paris 6) Laboratoire d’Hématologie, Hôpital Saint-AntoineParisFrance
  2. 2.Institut National de la Santé et de la Recherche Médicale, UMR 1009, Institut Gustave RoussyUniversité Paris Sud (Paris 11)VillejuifFrance
  3. 3.Université Denis Diderot (Paris 7)ParisFrance

Personalised recommendations